Medication info
Cevitera HCT Tablet 10/40/12.5 mg

Cevitera HCT Tablet 10/40/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Grayish-red round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2) / carton
Approval status
Active

MFDS item code 201805305 · Approved 2018.12.27 · Insurance code 698503970

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The strengths of the individual components are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, treatment should be started at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with the use of this medicine in patients 75 years and older, these patients should be monitored very carefully when receiving this medicine.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy

  • Essential hypertension
View approved original text

Combination therapy with Amlodipine and Olmesartan Medoxomil is used when blood pressure control is insufficient in patients with essential hypertension. These medications work by dilating blood vessels and lowering blood pressure, helping to manage blood pressure stably. They contribute to the effective control of patients' blood pressure and the prevention of cardiovascular complications. Therefore, this medication is used for the treatment of essential hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The strengths of the individual components are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, treatment should be started at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with the use of this medicine in patients 75 years and older, these patients should be monitored very carefully when receiving this medicine.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication may cause serious harm to the fetus and newborn in the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This drug is contraindicated in patients with allergies to this medication or its ingredients, or with specific heart, kidney, or liver diseases. Patients with excessively low blood pressure or in acute heart failure should not take this medication. Patients with reduced blood volume may experience hypotension when starting this drug, so careful monitoring is necessary. Patients with impaired kidney function should have regular checks of kidney function and electrolyte levels while taking this drug. Patients with poor liver function should also be specially cautious when using this medication. This drug may cause dizziness or lightheadedness because of its blood pressure-lowering effects; therefore, patients should avoid driving or operating hazardous machinery. In addition, this medication may interact with various other drugs, so if the patient is taking other medications, they must inform their physician or pharmacist. Overdose of this medication may result in severe hypotension or arrhythmias; if any unusual symptoms occur, the patient should visit a medical facility immediately. This medication is not recommended for children or adolescents under 18 years of age as its safety and efficacy have not been established. In the elderly, the sensitivity to the drug may increase due to decreased kidney and liver function, so starting with a lower dose and careful monitoring is necessary. Use of this medication during breastfeeding is not recommended, as continuing to breastfeed may cause adverse reactions in the infant. While taking this drug, patients should avoid excessive sun exposure and consult a physician immediately if any skin abnormalities occur.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, appetite loss, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, sensitivity to stimuli, anxiety, mood changes, sleep disturbances, dizziness, orthostatic dizziness, syncope, taste disturbance, hypertonicity, sensory loss, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, reduced tearing, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, bloating, dyspepsia, gastritis, stomach discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, vascular edema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, phototoxic reaction, pruritus, purpura, angioedema, rash, recurrence of lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paraplegia, myalgia, bone pain, frequent urination, acute kidney failure, hematuria, urinary disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated uric acid, reduced serum potassium, elevated gamma-glutamyltransferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, drug hypersensitivity, epigastric pain, reduced libido, labial edema, asthenia, altered consciousness, eczema, limb pain, mild decrease in mean hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distension, facial flush, epistaxis, benign prostatic hypertrophy, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. The storage temperature should be kept at room temperature between 1 and 30 degrees Celsius. This helps maintain the efficacy of the drug.

Appearance and packaging

Appearance

Grayish-red round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2) / carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.